Sanofi Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Sanofi hat ein Gesamteigenkapital von €74.4B und eine Gesamtverschuldung von €18.4B, wodurch sich der Verschuldungsgrad auf 24.8% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €126.5B bzw. €52.1B. Sanofi Das EBIT des Unternehmens beträgt €8.8B, so dass der Zinsdeckungsgrad 115.9 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €8.7B.

Wichtige Informationen

24.8%

Verhältnis von Schulden zu Eigenkapital

€18.42b

Verschuldung

Zinsdeckungsgrad	115.9x
Bargeld	€8.71b
Eigenkapital	€74.35b
Gesamtverbindlichkeiten	€52.11b
Gesamtvermögen	€126.46b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Apr 13

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Nov 19

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SANDie kurzfristigen Aktiva des Unternehmens (€30.7B) übersteigen seine kurzfristigen Passiva (€24.2B).

Langfristige Verbindlichkeiten: SANDie kurzfristigen Vermögenswerte des Unternehmens (€30.7B) übersteigen seine langfristigen Verbindlichkeiten (€27.9B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SANDie Nettoverschuldung im Verhältnis zum Eigenkapital (13.1%) wird als zufriedenstellend angesehen.

Schulden abbauen: SAN Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 41.7% auf 24.8% zurückgegangen.

Schuldendeckung: SANDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (55.7%).

Zinsdeckung: Die Zinszahlungen für die Schulden von SAN sind durch das EBIT gut gedeckt (115.9x coverage).

Sanofi Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Recent updates

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Consensus EPS estimates increase by 13%

Sanofi Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2023

New minor risk - Profit margin trend

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sanofi Announces CFO Changes, Effective April 1, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Sanofi to Report Q3, 2024 Results on Oct 25, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Sanofi Appoints Brian Foard as Head of Specialty Care Global Business Unit and Member of Executive Committee

Sanofi's (EPA:SAN) Price Is Right But Growth Is Lacking

Sanofi to Report Q4, 2023 Results on Feb 01, 2024

Sanofi Announces Dupixent Significantly Reduced (34%) Exacerbations, Confirming Positive Published Results from the Landmark Phase 3 Boreas Trial

Sanofi to Report Q2, 2024 Results on Jul 25, 2024

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Price target decreased by 8.3% to €106

Third quarter 2023 earnings: EPS misses analyst expectations

Sanofi Reiterates Earnings Guidance for the Year 2023

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen